

Reference:	FOI.17999.25
Subject:	Atopic Dermatitis
Date of Request:	4 August 2025

Requested:

1. How many patients were treated in the last 4 months (April to July 2025) by the dermatology department with each of the following products:

- Abrocitinib
- Acitretin
- Alitretinoin
- Azathioprine
- Baricitinib
- Ciclosporin
- Dupilumab
- Lebrikizumab
- Methotrexate
- Mycophenolate mofetil
- Pimecrolimus
- Phototherapy (UVB or PUVA) - for Atopic Dermatitis only
- Tacrolimus ointment
- Tralokinumab
- Upadacitinib
- Nemolizumab

2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department

- Abrocitinib
- Baricitinib
- Dupilumab
- Lebrikizumab
- Tralokinumab
- Upadacitinib
- Nemolizumab

*Patients are considered initiated on a treatment if they have not been treated with the named treatment in the previous 8 months.

3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

- 6 months to 5
- Age 6-11
- Age 12-17
- Age 18 and above

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of cases due to the low number (5 or less). Where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients, as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. The UHB provides within the table overleaf, the number of patients that were issued with the named biologic medications by the Dermatology department, during the period 1 April to 31 July 2025.

Medication	Number
Abrocitinib	0
Acitretin	46
Alitretinoin	*
Azathioprine	15
Baricitinib	0
Ciclosporin	10
Dupilumab	119
Lebrikizumab	*
Methotrexate	106
Mycophenolate mofetil	9
Pimecrolimus	0
Phototherapy (UVB or PUVA) - for Atopic Dermatitis only	0
Tacrolimus ointment	0
Tralokinumab	*
Upadacitinib	12
Nemolizumab	0

2. The UHB provides within the table below, the number of patients initiated on the named biologic medications by the Dermatology department, during the period 1 April to 31 July 2025.

Medication	Number
Abrocitinib	0
Baricitinib	0
Dupilumab	17
Lebrikizumab	*
Tralokinumab	0
Upadacitinib	*
Nemolizumab	0

3. The UHB provides within the table below, the age groups of patients that were issued with the biologic medications listed in question one (1), during the period 1 April to 31 July 2025.

Age Group	Number
6 months - 5	*
Age 6 – 11	8
Age 12 – 17	26
Age 18 and above	291